Results 71 to 80 of about 37,430 (216)

A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. [PDF]

PLoS ONE, 2015
Lenalidomide have both immunomodulatory and anti-angiogenic properties which could confer anti-cancer effects. The aim of this study was to assess the feasibility of combining lenalidomide with the standard treatment gemcitabine in pancreatic cancer ...
Gustav J Ullenhag, Eva Rossmann, Maria Liljefors   +2 more
doaj   +1 more source

Laboratory Identification of Pseudohypercalcemia Induced by Hyperglobulinemia in Multiple Myeloma: A Case Report

Journal of Clinical Laboratory Analysis, EarlyView.
Pseudohypercalcemia induced by calcium‐binding monoclonal immunoglobulin in multiple myeloma is verified via laboratory assays and validated by therapeutic response. ABSTRACT Background Pseudohypercalcemia is easily misdiagnosed in clinical practice, potentially leading to unnecessary interventions.
Anjiang Zhao, Fan Zhong, Yankui Liu, Guixing Li   +3 more
wiley   +1 more source

Molecular Glue Degraders in Early Development for Cancer Therapy

Medicinal Research Reviews, EarlyView.
ABSTRACT Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they ...
E. Sila Ozdemir, Hyunbum Jang, Ozlem Keskin, Attila Gursoy, Ruth Nussinov   +4 more
wiley   +1 more source

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma

, 2011
Purpose: Introduction of lenalidomide has expanded the therapeutic options for refractory and recurrent multiple myeloma (MM) patients. However, the application of the approved doses may be difficult in some patients due to adverse effects.
Glasmacher, Axel, German Refractory Myeloma Study Group, Gorschlüter, M, Glasmacher, A, Schmidt-Wolf, Ingo G. H., Schmidt-Wolf, IG, Gorschlüter, Marcus, Schwamborn, K, Schwamborn, Katharina   +8 more
core   +1 more source

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials [PDF]

, 2020
Bortezomib-melphalan-prednisone and continuous lenalidomide-dexamethasone represent the standard treatment of transplant-ineligible, newly diagnosed, multiple myeloma patients.
Sara Bringhen, Daniela Oddolo, Larocca, A., Laura Paris, Benevolo G., Bernardini A., Ledda, A., Montefusco, V., Paris, L., Zambello, R., Valeria Amico, Spada, Stefano, Mario Boccadoro, Musto P., Zambello R., Benevolo, G., Roman Hájek, Paris L., Giuliani, N., Spada, S., Vincenzo Fraticelli, Ledda, Antonio, Cangialosi, Clotilde, Hajek R., Mina, R., Patriarca, F., Falcone, Antonietta Pia, Hajek, Roman, Amico, Valeria, Francesca Patriarca, Liberati, A. M., Offidani M., Bringhen, S., Musto, Pellegrino, Amico V., De Paoli, Lorenzo, Fraticelli, V., Innao, Vanessa, Paris, Laura, Bernardini, A., Falcone, A. P., Spada S., Zambello, Renato, Boccadoro M., Evangelista A., Palumbo, Antonio, Evangelista, Andrea, Boccadoro, M., Alessandra Romano, Patriarca F., Antonio Palumbo, Bringhen, Sara, Oddolo D., Fraticelli V., Ledda A., Romano, A., Oddolo, D., Antonietta Pia Falcone, Mina, Roberto, de Paoli, L., Boccadoro, Mario, Giulia Benevolo, Offidani, Massimo, Amico, V., Oddolo, Daniela, Vittorio Montefusco, Innao, V., Evangelista, A., Cangiolosi, C., Roberto Mina, Musto, P., Antonio Ledda, Romano, Alessandra, Patriarca, Francesca, Innao V., Benevolo, Giulia, Bringhen S., Falcone A. P., Mina R., Montefusco, Vittorio, Hajek, R., Giuliani N., Vanessa Innao, Clotilde Cangiolosi, Annalisa Bernardini, Cangiolosi C., Fraticelli, Vincenzo, Giuliani, Nicola, Massimo Offidani, Lorenzo De Paoli, Nicola Giuliani, Alessandra Larocca, Andrea Evangelista, Renato Zambello, de Paoli L., Bernardini, Annalisa, Romano A., Palumbo, A., Anna Marina Liberati, Montefusco V., Liberati, Anna Marina, Offidani, M., Liberati A. M., Pellegrino Musto, Larocca A., Stefano Spada, Palumbo A., Larocca, Alessandra   +107 more
core   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Real‐World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Benjamin Reardon, Ian Kerridge, Tasman Armytage   +2 more
wiley   +1 more source

Lenalidomide in Relapsed and Refractory Multiple Myeloma

, 2020
Improvement in the treatment options in multiple myeloma(MM) makes the survival rate into double during recent years but most of the patient eventually relapses.
Dattatreya Mukherjee
core   +1 more source

Expanding role of lenalidomide in hematologic malignancies

, 2015
Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration
Bhutani M, Ghosh N, Fasan O, Grunwald MR
core